Cancer

May 17, 2021

Doxorubicin Chemoembolization For Hepatocellular Carcinoma

What is Doxorubicin Transarterial Chemoembolization (TACE)? Known as doxorubicin chemoembolization.
March 23, 2021

Easy Durvalumab Dosing – 2 MCQs

What is Durvalumab, and how it works? Well, it’s basically an immunoglobulin monoclonal antibody, it works by a very cool trick; where it affects on the […]
January 15, 2021

3 Highlights about Ovarian Cancer: Options and Risks

This is an important thing that's our patients are worried about this. And this is something that we, as a group need to ask ourselves, how can we improve our adherence? and how to deal with ovarian cancer: options and risks
January 15, 2021

4 Dimensions to Improve Cancer Patient Quality Of Life

Cancer care is advancing. And we have more and more clinical trials, as well as new agents that we need to always remain focused on what our treatments mean, in terms of quality of life for patients and for their families. Because for all of us, quality of life, remains the ultimate goal of all of our cancer treatments. # Cancer Patient Quality Of Life
January 1, 2021

Opioids for Managing Cancer Pain

We need opioids to manage cancer pain and NCCN gives clear guidelines on how to properly utilize them.
December 25, 2020

Simple Ways to Manage Lynparza/Olaparib-Induced Nausea Ovarian Cancer

Simple Ways to Manage Lynparza/Olaparib-Induced Nausea Ovarian Cancer
December 24, 2020

How Helpful are The Ovarian Cancer Guidelines? [Free Thoughts]

How Helpful are The Ovarian Cancer Guidelines? I think certainly in the future coming up next few years, we're gonna see a lot of strides, a lot of treatment advances
December 24, 2020

3 Ways to Manage Lynparza/Olaparib-Induced Fatigue Ovarian Cancer

3 Ways to Manage Lynparza/Olaparib-Induced Fatigue Ovarian Cancer.
December 23, 2020

Top 3 Ovarian Cancer Molecules : Super PARP Inhibitors

Top 3 Ovarian Cancer Molecules : The Role of PARP Inhibitors. Taking a quick look at Niraparib, Rucaparib and Olaparib.
gdpr-image
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more